agilon health Balance Sheet Health

Financial Health criteria checks 0/6

Key information

5.8%

Debt to equity ratio

US$38.56m

Debt

Interest coverage ratio	n/a
Cash	US$488.34m
Equity	US$661.02m
Total liabilities	US$1.08b
Total assets	US$1.74b

Recent financial health updates

Is agilon health (NYSE:AGL) Using Too Much Debt?

Apr 04

Recent updates

An Intrinsic Calculation For agilon health, inc. (NYSE:AGL) Suggests It's 35% Undervalued

Jun 06

Is It Time To Consider Buying agilon health, inc. (NYSE:AGL)?

Apr 28

agilon gains after boosting Medicare membership outlook

Jan 09

Is There An Opportunity With agilon health, inc.'s (NYSE:AGL) 39% Undervaluation?

Dec 19

agilon health: Back To Long-Term Range, Despite Underlying Market Growth

Dec 15

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

agilon health Balance Sheet Health

Financial Health criteria checks 0/6

Key information

Recent financial health updates

Is agilon health (NYSE:AGL) Using Too Much Debt?

Recent updates

agilon health, inc., Annual General Meeting, May 29, 2024

agilon health: Still Not Healthy Enough To Warrant Upside

agilon health, inc. to Report Q1, 2024 Results on May 07, 2024

Is agilon health (NYSE:AGL) Using Too Much Debt?

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit against agilon health, inc

Gainey Mckenna & Egleston Announces Files Second Class Action Lawsuit Against agilon health, inc

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit File Against agilon health, inc

New minor risk - Profitability

Consensus EPS estimates fall by 280%, revenue upgraded

agilon health, inc. Revises Revenue Guidance for the Full Year Ending December 31, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2026

Price target decreased by 7.5% to US$11.97

agilon health, inc. to Report Q4, 2023 Results on Feb 27, 2024

agilon health, inc. Announces Executive Changes

Chairman of the Board exercised options to buy US$8.8m worth of stock.

Consensus EPS estimates fall by 24%

Forecast breakeven date pushed back to 2025

agilon health, inc. Revises Earnings Guidance for the Year Ended December 31, 2023

Agilon Health, Inc. Announces Retirement of Timothy Bensley as Chief Financial Officer During 2024

Price target decreased by 11% to US$19.60

Price target decreased by 8.1% to US$22.00

President recently bought US$498k worth of stock

agilon health: High Growth But Unsustainable Economics

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 14%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

An unknown buyer acquired MDX Hawaii, Inc. from agilon health, inc. (NYSE:AGL).

agilon health, inc. to Report Q3, 2023 Results on Nov 02, 2023

Chief Markets Officer notifies of intention to sell stock

agilon health: Strong Sales Growth, Lacks Remaining Value Drivers

Chief Markets Officer exercised options and sold US$548k worth of stock

agilon Health, Inc. Announces Executive Changes

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

agilon health, inc. Revises Financial Guidance for the Fiscal Year 2023

Market Participants Recognise agilon health, inc.'s (NYSE:AGL) Revenues

Chief Markets Officer exercised options and sold US$493k worth of stock

agilon health, inc. to Report Q2, 2023 Results on Aug 03, 2023

agilon health: A Hold Until Margins Are Improved

agilon health, inc. Announces Executive Changes

Agilon Health Names Silvana Battaglia to Board of Directors

Chief Markets Officer exercised options and sold US$559k worth of stock

An Intrinsic Calculation For agilon health, inc. (NYSE:AGL) Suggests It's 35% Undervalued

agilon health, inc. has completed a Follow-on Equity Offering in the amount of $1.868014 billion.

agilon health, inc. has completed a Follow-on Equity Offering in the amount of $1.868014 billion.

Chief Strategy & Development Officer exercised options and sold US$104k worth of stock

Forecast to breakeven in 2024

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

agilon health, inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2023 and Year Ending December 31, 2023

Is It Time To Consider Buying agilon health, inc. (NYSE:AGL)?

Chief Markets Officer exercised options and sold US$1.2m worth of stock

Consensus EPS estimates fall by 13%

Now 20% undervalued

Chief Markets Officer recently sold US$833k worth of stock

Independent Director notifies of intention to sell stock

Chief Medical & Quality Officer exercised options and sold US$249k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

High number of new directors

Chief Markets Officer notifies of intention to sell stock

Now 20% undervalued

Chief Medical & Quality Officer notifies of intention to sell stock

agilon health, inc. to Report Q4, 2022 Results on Mar 01, 2023

Chief Markets Officer exercised options and sold US$783k worth of stock

agilon gains after boosting Medicare membership outlook

Forecast breakeven date moved forward to 2023

agilon health, inc. Announces Resignation of Michelle A. Gourdine

Is There An Opportunity With agilon health, inc.'s (NYSE:AGL) 39% Undervaluation?

Chief Markets Officer exercised options and sold US$540k worth of stock

agilon health: Back To Long-Term Range, Despite Underlying Market Growth

Forecast breakeven date pushed back to 2024

Chief Markets Officer exercised options and sold US$552k worth of stock

Forecast breakeven date pushed back to 2024

High number of new directors

Consensus forecasts updated